Yusuke Tsukagoshi
YOU?
Author Swipe
View article: Low Power Long Duration Ablation for High Impedance Left Ventricular Summit <scp>PVCs</scp>
Low Power Long Duration Ablation for High Impedance Left Ventricular Summit <span>PVCs</span> Open
Low-power, long-duration (LPLD) ablation (≤ 25 W for ≥ 60 s with 30 mL/min irrigation) was applied to high-impedance (≥ 150 Ω) left ventricular summit PVC sites via the anterior interventricular vein. Power was escalated stepwise (10 W → 1…
View article: Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non‐small cell lung cancer receiving <scp>EGFR‐TKI</scp> treatment
Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non‐small cell lung cancer receiving <span>EGFR‐TKI</span> treatment Open
Background Lung cancer is the leading cause of cancer‐related deaths. Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are effective for advanced non‐small cell lung cancer (NSCLC) harboring EGFR mutations, …
View article: An Exploratory Randomized Phase II Trial Comparing CDDP Plus S-1 With Bevacizumab and CDDP Plus Pemetrexed With Bevacizumab Against Patients With Advanced Non-squamous Non-small Cell Lung Cancer
An Exploratory Randomized Phase II Trial Comparing CDDP Plus S-1 With Bevacizumab and CDDP Plus Pemetrexed With Bevacizumab Against Patients With Advanced Non-squamous Non-small Cell Lung Cancer Open
The combination regimen of SCB was identified as having a similar activity and tolerability to that of PCB in patients with advanced non-squamous NSCLC.
View article: Post-treatment Glasgow Prognostic Score Predicts Efficacy in Advanced Non-small-cell Lung Cancer Treated With Anti-PD1
Post-treatment Glasgow Prognostic Score Predicts Efficacy in Advanced Non-small-cell Lung Cancer Treated With Anti-PD1 Open
The post-treatment GPS independently predicted efficacy of anti-PD1 treatment for NSCLC.
View article: Dual inhibition of MEK and p38 impairs tumor growth in KRAS‑mutated non‑small cell lung cancer
Dual inhibition of MEK and p38 impairs tumor growth in KRAS‑mutated non‑small cell lung cancer Open
Despite the high frequency of KRAS mutations in non-small cell lung cancer (NSCLC), therapeutic modalities targeting KRAS-mutated NSCLC have not been established. Based on our previous findings that mutant KRAS knockdo…
View article: Small Cell Lung Cancer with Sarcoidosis in Spontaneous Remission: A Case Report
Small Cell Lung Cancer with Sarcoidosis in Spontaneous Remission: A Case Report Open
A 69-year-old woman was diagnosed with sarcoidosis, which was not treated with corticosteroid therapy. Her levels of angiotensin converting enzyme decreased significantly over 4 years and a mass lesion was detected near the lower part of h…
View article: P2.01-027 Clinical Significance of Topoisomerase-II Expression in Patients with Non-Small Cell Lung Cancer Treated with Amrubicin
P2.01-027 Clinical Significance of Topoisomerase-II Expression in Patients with Non-Small Cell Lung Cancer Treated with Amrubicin Open
View article: P2.15-016 Clinical Significance of Topoisomerase-II Expression in Patients with Relapsed HGNEC of the Lung Treated with Amrubicin
P2.15-016 Clinical Significance of Topoisomerase-II Expression in Patients with Relapsed HGNEC of the Lung Treated with Amrubicin Open
View article: The Onset of Eosinophilic Pneumonia Preceding Anti-synthetase Syndrome
The Onset of Eosinophilic Pneumonia Preceding Anti-synthetase Syndrome Open
A 66-year-old man had been treated with prednisolone for eosinophilic pneumonia for 8 years. His slowly progressing cough and dyspnea were accompanied by elevated levels of fibrotic serological markers and an increased reticular shadow on …
View article: An Autopsy Case of Fulminant Hepatitis in a Patient with Multiple Sclerosis Treated by Interferon-Beta-1a
An Autopsy Case of Fulminant Hepatitis in a Patient with Multiple Sclerosis Treated by Interferon-Beta-1a Open
A 44-year-old woman with multiple sclerosis (MS) receiving interferon (IFN)-beta-1a treatment was admitted to a local hospital for severe icterus and liver injury. She was transferred to our university hospital because fulminant hepatitis …
View article: Isoniazid-induced Pure Red Cell Aplasia in a Patient with Sarcoidosis: A Patient Summary and Review of the Literature
Isoniazid-induced Pure Red Cell Aplasia in a Patient with Sarcoidosis: A Patient Summary and Review of the Literature Open
A 41-year-old woman treated with isoniazid (INH) for latent tuberculosis infection and an oral corticosteroid for sarcoidosis developed severe anemia two months after initiating INH. A bone marrow examination showed erythroblastopenia, and…